Medication for Osteopenia: Hip Fracture Risk Threshold
Pharmacologic therapy should be initiated for patients with osteopenia (T-score between -1.0 and -2.5) when the FRAX 10-year hip fracture probability is ≥3% or major osteoporotic fracture probability is ≥20%. 1, 2
Treatment Thresholds for Osteopenia
The most recent AACE/ACE guidelines (2020) provide clear, evidence-based thresholds for initiating medication in patients with osteopenia:
- 10-year hip fracture risk ≥3% (using FRAX)
- OR 10-year major osteoporotic fracture risk ≥20% (using FRAX)
These thresholds apply specifically to patients with T-scores between -1.0 and -2.5 at the spine, femoral neck, total hip, or 1/3 radius 1, 2. This is a Grade A, BEL 1 recommendation, representing the strongest level of evidence available.
Additional Indications for Treatment in Osteopenia
Beyond FRAX thresholds, pharmacologic therapy is strongly recommended (Grade A) for patients with osteopenia who have:
This represents an absolute indication regardless of FRAX score, as prior fracture dramatically elevates future fracture risk.
Risk Stratification Context
The Endocrine Society (2019) algorithm similarly defines high fracture risk as:
- Prior spine or hip fracture
- T-score ≤-2.5 at hip or spine
- 10-year hip fracture risk ≥3%
- 10-year major osteoporotic fracture risk ≥20% 3
Multiple guidelines converge on these same thresholds, providing robust consensus 4, 5.
Very High Risk Considerations
For patients with osteopenia meeting very high risk criteria, consider more potent initial therapy:
- Recent fracture (within 12 months)
- Multiple fractures
- Very high FRAX scores (major osteoporotic fracture >30%, hip fracture >4.5%)
- Very low T-score (less than -3.0)
- High fall risk 1, 2
In these cases, consider abaloparatide, denosumab, romosozumab, teriparatide, or zoledronic acid as initial therapy rather than oral bisphosphonates 1.
First-Line Treatment Options
For patients with osteopenia meeting treatment thresholds:
Standard risk: Oral bisphosphonates (alendronate, risedronate) are appropriate first-line agents 1, 2
High/very high risk: Consider zoledronic acid (IV annually) or denosumab (subcutaneous every 6 months) for better adherence and efficacy 1, 3
Critical Caveats
FRAX limitations to recognize:
- Does not account for fall frequency, number of prior fractures, or frailty 6
- Requires glucocorticoid dose adjustment if prednisone >7.5 mg/day (multiply hip fracture risk by 1.2, major osteoporotic fracture by 1.15) 6, 7, 6
- Not validated for patients <40 years old 6, 7
- May underestimate risk in patients with very high glucocorticoid doses (≥30 mg/day) 6
Important clinical reality: Research shows that 85% of patients meeting FRAX high-risk thresholds actually have T-scores in the osteoporotic range at one or more measurement sites 8. Conversely, <1% of high-risk patients have normal T-scores at all sites. This means the 3%/20% thresholds effectively capture most patients who would benefit from treatment.